<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491373</url>
  </required_header>
  <id_info>
    <org_study_id>C-9504</org_study_id>
    <nct_id>NCT01491373</nct_id>
  </id_info>
  <brief_title>Pilot Study of rhBMP-2/ACS/LT-CAGE® for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease</brief_title>
  <official_title>A Feasibility Investigation of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Degenerative Disc Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the feasibility of recombinant human bone morphogenetic&#xD;
      protein-2 and absorbable collagen sponge with the tapered interbody fusion device (LT-CAGE® )&#xD;
      for anterior lumbar interbody fusion in patients with degenerative disc disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <completion_date type="Actual">September 1999</completion_date>
  <primary_completion_date type="Actual">September 1999</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fusion</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Assessment (Oswestry Disability Index, ODI)</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Status Assessment</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status assessment (SF-36)</measure>
    <time_frame>24 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Degeneration of Lumbar Intervertebral Disc</condition>
  <arm_group>
    <arm_group_label>rhBMP-2/ACS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Autograft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>rhBMP-2/ACS/LT-CAGE® Device</intervention_name>
    <description>rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.</description>
    <arm_group_label>rhBMP-2/ACS</arm_group_label>
    <other_name>Recombinant human bone morphogenetic protein-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Autograft/LT-CAGE® Device</intervention_name>
    <description>LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest</description>
    <arm_group_label>Autograft</arm_group_label>
    <other_name>Autogenous bone graft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has degenerative disc disease as noted by back pain of discogenic origin with&#xD;
             degeneration of the disc confirmed by radiographic studies.&#xD;
&#xD;
          2. Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification&#xD;
             (Meyerding HW, 1932.)&#xD;
&#xD;
          3. Has single level symptomatic degenerative involvement from L2 to S1.&#xD;
&#xD;
          4. Is between the ages of 18 and 65, inclusive, at the time of surgery.&#xD;
&#xD;
          5. Is willing to comply with the study plan and sign the Patient Informed Consent Form.&#xD;
&#xD;
          6. Has not responded to conservative treatment for a period of 5 months.&#xD;
&#xD;
          7. If of child-bearing potential, subject is non-pregnant (documented by a negative&#xD;
             Pregnancy test within 72 hours of surgery), non-nursing female who agrees to use&#xD;
             adequate contraception for 16 weeks following surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has spinal condition other than symptomatic degenerative disc disease at the involved&#xD;
             surgical level.&#xD;
&#xD;
          2. Had previous anterior surgical procedures at the involved spinal level.&#xD;
&#xD;
          3. Has a condition which requires postoperative medications that interfere with fusion&#xD;
             such as steroids or nonsteroidal anti-inflammatory drugs. (This does not include low&#xD;
             dose aspirin for prophylactic anticoagulation.)&#xD;
&#xD;
          4. Has osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation&#xD;
             would be contraindicated.&#xD;
&#xD;
          5. Has circulatory problems, such as thrombophlebitis, lymphedema, or vascular deficiency&#xD;
             at the implant site.&#xD;
&#xD;
          6. Has symptomatic cardiac disease.&#xD;
&#xD;
          7. Has presence of active malignancy or history of cancer in the past 5 years.&#xD;
&#xD;
          8. Has overt or active infection.&#xD;
&#xD;
          9. Is obese, i.e., weight greater than 40% over ideal for their age and height.&#xD;
&#xD;
         10. Has fever (temperature &gt; 101°F oral).&#xD;
&#xD;
         11. Has local inflammatory signs indicative of infection.&#xD;
&#xD;
         12. Has a documented metal allergy or intolerance.&#xD;
&#xD;
         13. Is involved in a worker's compensation or unresolved spinal litigation case.&#xD;
&#xD;
         14. Is mentally incompetent (either documented or in the opinion of the investigator).&#xD;
&#xD;
         15. Has psychogenic magnification of pain (in the opinion of the investigator).&#xD;
&#xD;
         16. Is a prisoner.&#xD;
&#xD;
         17. Is pregnant.&#xD;
&#xD;
         18. Is an alcohol and/or substance abuser.&#xD;
&#xD;
         19. Requires bone growth stimulation in the lumbar spine.&#xD;
&#xD;
         20. Is a tobacco user at the time of surgery.&#xD;
&#xD;
         21. Patient has received drugs which may interfere with bone metabolism within two weeks&#xD;
             prior to the planned date of spinal fusion surgery (e.g., steroids or methotrexate).&#xD;
&#xD;
         22. Patient has a history of autoimmune disease (systemic lupus erythematosus or&#xD;
             dermatomyositis).&#xD;
&#xD;
         23. The subject has a history of exposure to injectable collagen implants.&#xD;
&#xD;
         24. Patient's history includes hypersensitivity to protein pharmaceuticals (monoclonal&#xD;
             antibodies or gamma globulins) or collagen.&#xD;
&#xD;
         25. Patient has received treatment with an investigational therapy within 28 days prior to&#xD;
             implantation surgery or such treatment is planned during the 16 weeks following&#xD;
             rhBMP-2/ACS implantation.&#xD;
&#xD;
         26. Patient has received any previous exposure to BMP.&#xD;
&#xD;
         27. The patient requires allograft or bone substitute as part of treatment.&#xD;
&#xD;
         28. Patient has history of endocrine or metabolic disorder known to affect osteogenesis&#xD;
             (e.g. Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis&#xD;
             imperfecta).&#xD;
&#xD;
         29. Patient in the physician's opinion, would not be a good candidate for this surgical&#xD;
             procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Degenerative Disc Disease</keyword>
  <keyword>Symptomatic Degenerative Disc Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

